This analyst just upped his price target on Knight Therapeutics

Research Capital analyst Andre Uddin raised his target on Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:GUD) to C$9.80 from C$8.55, maintaining a “Buy” rating in a May 7 report after what he called another strong quarter.

Knight reported Q1 revenue of $148.4-million, up 69% year-over-year and ahead of Uddin’s $110.2-million estimate and consensus near $113.5-million. Adjusted EBITDA was $27.9-million, up 130% and above his $16.5-million forecast.

Management raised 2026 revenue guidance to $510-million to $525-million from $490-million to $510-million.

“We expect GUD to have their debt repaid by 2027 assuming there are no further product or company acquisitions,” Uddin said.

The analyst said new product launches should support growth, including Pemazyre in Argentina, Akynzeo in Paraguay, Minjuvi for follicular lymphoma, and Bapocil in Colombia. He also noted Niktimvo has been submitted for approval in Brazil.

Uddin expects Knight to generate Adjusted EBITDA of $77.5-million on revenue of $514.2-million in fiscal 2026, improving to $79.4-million on revenue of $519.8-million in fiscal 2027.

-30-